Drugs News and Research

RSS

Zalicus advancing Z944 into further clinical development

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it is advancing Z944, its novel oral T-type calcium channel blocker, into further clinical development in the third quarter of 2013.

4 Jun 2013

Naurex initiates Phase I trial of NRX-1074 in normal volunteers

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced that it has begun patient dosing in a Phase I trial of its novel, orally active agent NRX-1074.

4 Jun 2013

New technique selectively represses unwanted immune reactions without disabling immune system

The human immune system is remarkably efficient, but sometimes its attack is misdirected, leading to allergies, autoimmune diseases and rejection of transplant organs and therapeutic drugs. Current immune suppressants have major drawbacks, but a team from The Scripps Research Institute (TSRI) has demonstrated a new technique that may lead to a better way to selectively repress unwanted immune reactions without disabling the immune system as a whole.

4 Jun 2013

Duke University is awarded $2M to initiate new clinical research network on antibacterial resistance

Duke University, Durham, N.C., has been awarded $2 million to initiate a new clinical research network focused on antibacterial resistance. Total funding for the leadership group cooperative agreement award could reach up to $62 million through 2019.

4 Jun 2013

Baylor Endocrine Center seeks volunteers to compare long-term benefits and risks of diabetes drugs

Baylor Endocrine Center is looking for volunteers to take part in a study to compare the long-term benefits and risks of four widely used diabetes drugs in combination with metformin, the most common first-line medication for treating type 2 diabetes. The project is called the GRADE: Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study.

4 Jun 2013

Report: 83% of cancer doctors face oncology drug shortages

Eighty-three percent of cancer doctors report that they've faced oncology drug shortages, and of those, nearly all say that their patients' treatment has been impacted, according to a study from researchers at the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania that will be presented today at the 2013 annual meeting of the American Society of Clinical Oncology (Abstract #CRA6510).

4 Jun 2013

Researchers establish link between abnormal structure of synapses and behavioral abnormalities of brain circuits in FXS

Fragile X syndrome (FXS) is a genetic malady that is the most common inherited cause of autism and intellectual disability. Brain scientists know the gene defect that causes FXS, and the damage it does-- misshaping the brain's synapses, the connections between neurons. But how that abnormal shaping of synapses translates to abnormal behavior is unclear.

4 Jun 2013

Discovery could reveal potential new drug options for malaria treatment

Malaria parasites that develop resistance to the most effective class of anti-malarial drugs may become susceptible to other treatments as a result. The discovery could reveal potential new drug options, which would be essential in the event of resistance to the best anti-malarials.

4 Jun 2013

Vitamin C and gout: an interview with Prof. Lisa Stamp

A previous study in by Choi et al in the USA showed that people with a higher vitamin C intake have a lower risk of gout. There are also studies in healthy volunteers that suggest that vitamin C supplements reduce blood uric acid levels.

4 Jun 2013

Cardiovascular disease: The leading cause of death in UK

Cardiovascular disease is the leading cause of death in the UK, accounting for a third of all fatalities through illnesses such as stroke and heart disease.

4 Jun 2013

Debiopharm evaluates Debio 1143 in combination with Carboplatin and Paclitaxel in NSCLC patients

Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.

4 Jun 2013

Cancer immunotherapy shows promise in treating patients with metastatic tumors

Cancer immunotherapy is showing promise in treating patients with a variety of advanced, metastatic tumors, as evidenced by two newly unveiled studies from Yale Cancer Center.

4 Jun 2013

Viewpoints: Current insurance was made cheaper by turning away the sick; Even in Obama's Illinois, implementing changes is tough

Some people will find the new rules make insurance more expensive. That's in part because their health insurance was made cheap by turning away sick people. The new rules also won't allow for as much discrimination based on age or gender. The flip side of that, of course, is that many will suddenly find their health insurance is much cheaper, or they will find that, for the first time, they're not turned away when they try to buy health insurance (Ezra Klein, 6/1).

4 Jun 2013

Early detection methods can help cure cervical cancer

Cervical cancer, a disease that will affect more than 12,000 women in the United States this year and more than a half million women worldwide, leads to significantly fewer deaths when effective early detection methods are available, either via a Pap smear or with a test for presence of the human papilloma virus.

4 Jun 2013

Duke Medicine, UCSF investigators to oversee research program on antibacterial resistance

Investigators at Duke Medicine and the University of California, San Francisco have been selected to oversee a nationwide research program on antibacterial resistance, which includes a focus on the growing unmet challenges associated with methicillin-resistant Staphylococcus aureus and E. coli.

4 Jun 2013

Scientists work together to optimize the quality, availability of fecal microbiota transplants

Monarch Labs and the BioTherapeutics, Education & Research Foundation announced today their collaboration to develop two fecal microbiota transplantation products.

4 Jun 2013

People with narcolepsy have increased number of neurons that produce histamine

A new study provides surprising evidence that people with narcolepsy have an increased number of neurons that produce histamine, suggesting that histamine signaling may be a novel therapeutic target for this potentially disabling sleep disorder.

4 Jun 2013

Researchers identify a new mechanism that appears to suppress tumor growth

Researchers at the University of California, San Diego School of Medicine, with colleagues at the University of Rochester Medical Center, have identified a new mechanism that appears to suppress tumor growth, opening the possibility of developing a new class of anti-cancer drugs.

4 Jun 2013

Study: Mutations in gene NTRK1 cause a subset of lung cancers

To the list of oncogenic drivers of lung cancer that includes ALK, EGFR, ROS1 and RET, results of a University of Colorado Cancer Center study presented at ASCO 2013 show that mutations in the gene NTRK1 cause a subset of lung cancers.

4 Jun 2013

Study provides important details for recently identified target in lung adenocarcinoma

In results presented at ASCO 2013, a University of Colorado Cancer Center study provides important details for a recently identified driver and target in lung adenocarcinoma: rearrangement of the gene RET.

4 Jun 2013

Drugs News and Research

Zalicus advancing Z944 into further clinical development

Naurex initiates Phase I trial of NRX-1074 in normal volunteers

New technique selectively represses unwanted immune reactions without disabling immune system

Duke University is awarded $2M to initiate new clinical research network on antibacterial resistance

Baylor Endocrine Center seeks volunteers to compare long-term benefits and risks of diabetes drugs

Report: 83% of cancer doctors face oncology drug shortages

Researchers establish link between abnormal structure of synapses and behavioral abnormalities of brain circuits in FXS

Discovery could reveal potential new drug options for malaria treatment

Vitamin C and gout: an interview with Prof. Lisa Stamp

Cardiovascular disease: The leading cause of death in UK

Debiopharm evaluates Debio 1143 in combination with Carboplatin and Paclitaxel in NSCLC patients

Cancer immunotherapy shows promise in treating patients with metastatic tumors

Viewpoints: Current insurance was made cheaper by turning away the sick; Even in Obama's Illinois, implementing changes is tough

Early detection methods can help cure cervical cancer

Duke Medicine, UCSF investigators to oversee research program on antibacterial resistance

Scientists work together to optimize the quality, availability of fecal microbiota transplants

People with narcolepsy have increased number of neurons that produce histamine

Researchers identify a new mechanism that appears to suppress tumor growth

Study: Mutations in gene NTRK1 cause a subset of lung cancers

Study provides important details for recently identified target in lung adenocarcinoma

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News